Takeda Pharmaceutical (TAK) Net Income towards Common Stockholders Growth (1y) (2018 - 2026)
Takeda Pharmaceutical (TAK) Net Income towards Common Stockholders Growth (1y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.11 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.27 Bn | 39.61 Bn | 2.15 Bn | -304.98% |
| 3 | Zoetis | 31.81 Bn | 30.14 Bn | 1.05 Bn | -5.04% |
| 4 | Takeda Pharmaceutical | 28.72 Bn | 22.92 Bn | 5.10 Bn | -17.29% |
| 5 | United Therapeutics | 22.19 Bn | 19.53 Bn | 683.80 Mn | 7.59% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -2,482.61% |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 34.33% |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 390.91% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Alkermes | 8.14 Bn | 7.48 Bn | 397.90 Mn | -99.40% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -17.29% |
| Mar 31, 2026 | -2.72% |
| Dec 31, 2025 | -252.74% |
| Sep 30, 2025 | 3.63% |
| Jun 30, 2025 | 40.33% |
| Mar 31, 2025 | 26.73% |
| Dec 31, 2024 | -422.64% |
| Sep 30, 2024 | -28.51% |
| Jun 30, 2024 | -6.20% |
| Mar 31, 2024 | -19.07% |
| Dec 31, 2023 | -75.05% |
| Sep 30, 2023 | 342.84% |
| Jun 30, 2023 | -19.67% |
| Mar 31, 2023 | 912.20% |
| Dec 31, 2022 | 65.92% |
| Sep 30, 2022 | 7.07% |
| Jun 30, 2022 | -35.44% |
| Mar 31, 2022 | -105.25% |
| Dec 31, 2021 | -42.50% |
| Sep 30, 2021 | 998.23% |